Central Pharmaceuticals (DHA:CENTRALPHL) Moat Score: 0/10 (As of Aug. 04, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

DHA:CENTRALPHL Central Pharmaceuticals Ltd DHA:CENTRALPHL
66 GF Score
Price BDT12.00
GF Value BDT12.06
Valuation Fairly Valued
! 5 Warning Signs
View Full Analysis

What is Central Pharmaceuticals Moat Score?

Central Pharmaceuticals has the Moat Score of 0, which implies that the company might have No Moat - No discernible moat.

Central Pharmaceuticals has

Moat Score is a ranking system developed by GuruFocus to assess a company's ability to sustain a competitive advantage, rated on a scale from 0 to 10. It takes into account key factors such as market leadership, cost advantages, network effects, customer switching costs, and more.

The company's Moat Score is based on these criteria:

1. Market leadership and sustainable market share
2. Network effects and significant customer switching costs
3. Valuable intellectual property and patents
4. Strong brand strength and deep customer loyalty
5. Durable cost advantages (e.g., economies of scale, proprietary technology)
6. Significant regulatory barriers and exclusive licenses
7. Superior distribution network
8. Strong and sustainable pricing power
9. Consistent and impactful innovation and R&D capabilities

Based on the research, GuruFocus believes Central Pharmaceuticals might have No Moat - No discernible moat.

Central Pharmaceuticals  (DHA:CENTRALPHL) Moat Score Explanation

The Moat Score ranges from 0 to 10, with 10 as the highest. GuruFocus divided Moat Score into following 8 categories:

Moat Score Moat Level
10Wide Moat - Exceptionally dominant and durable wide moat
8 - 9Wide Moat - Clear and robust wide moat
7Wide Moat - Entry-level wide moat, clearly possessing durable advantages
6Narrow Moat - Strong narrow moat, clearly distinguishable but not wide
5Narrow Moat - Solid narrow moat
4Narrow Moat - Discernible but modest moat
1 - 3No Moat - Very weak/transient advantages
0No Moat - No discernible moat

Central Pharmaceuticals Moat Score Related Terms

DHA:CENTRALPHL
66GF Score
Central Pharmaceuticals Ltd DHA:CENTRALPHL
Moat Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Central Pharmaceuticals (DHA:CENTRALPHL) Overvalued in 2026?

Based on GuruFocus' analysis, Central Pharmaceuticals stock appears to be undervalued. The current stock price of BDT12.00 is trading 0.5% below its estimated GF Value™ of BDT12.06. GuruFocus considers Central Pharmaceuticals to be Fairly Valued.

Key valuation signals for DHA:CENTRALPHL:

  • Moat Score: 0
  • GF Value™: BDT12.06 vs. price of BDT12.00 (0.5% below fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the DHA:CENTRALPHL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Central Pharmaceuticals Business Description

Address South West Darus Salam Road, 2-A/1, 2nd Floor, Mirpur - 1, Dhaka, BGD, 1216
Central Pharmaceuticals Ltd is engaged in the manufacturing and marketing of medicines in Bangladesh. The company manufactures finished pharmaceutical formulations, including tablets, capsules, liquids, ointments, and injectables, covering therapeutic areas such as anti-infectives, cardiovascular treatments, pain management, and gastrointestinal remedies. It conducts production and sales exclusively in the domestic market through its own facilities and distribution network. The company generates revenue from the sales of its pharmaceutical preparations.
66GF Score

Get the complete analysis for DHA:CENTRALPHL

Moat Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

BDT12.00
Price
BDT12.06
GF Value